(Q27853272)

English

Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): ...

scientific article (publication date: December 2015)

In more languages

Statements

scholarly article

0 references

Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial (English)

0 references

0 references

brain metastasis

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Federico Piacentini

15

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26596672%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

16

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26596672%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

20

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26596672%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Thomas Bachelot

5

object named as

Thomas Bachelot

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26596672%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

17

object named as

Petri Bono

1 reference

Europe PubMed Central

PubMed publication ID

7 June 2020

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26596672%20AND%20SRC:MED&resulttype=core&format=json

Pirkko-Liisa Kellokumpu-Lehtinen

13

object named as

Pirkko-Liisa Kellokumpu-Lehtinen

1 reference

Europe PubMed Central

PubMed publication ID

7 June 2020

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26596672%20AND%20SRC:MED&resulttype=core&format=json

author name string

Javier Cortés

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26596672%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Véronique Dieras

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26596672%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Jungsil Ro

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26596672%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Jérôme Barriere

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26596672%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Sara Hurvitz

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26596672%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Emilie Le Rhun

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26596672%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Marc Espié

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26596672%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Sung-Bae Kim

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26596672%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Joo Hyuk Sohn

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26596672%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Jean-Marc Nabholtz

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26596672%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Julie Taguchi

14

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26596672%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Mahmoud Ould-Kaci

18

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26596672%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Flavien Roux

19

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26596672%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Andreas Schneeweiss

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26596672%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

publication date

December 2015

0 references

Lancet Oncology Commission

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26596672%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

16

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26596672%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

16

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26596672%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

1700-1710

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26596672%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Recommendations on disease management for patients with advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases: American Society of Clinical Oncology clinical practice guideline.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900373-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Central Nervous System Metastases in HER-2 Positive Metastatic Breast Cancer Patients Treated with Trastuzumab: Incidence, Survival, and Risk Factors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900373-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Brain metastases in breast cancer: clinical and pathologic characteristics associated with improvements in survival

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900373-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Survival in patients with brain metastases from breast cancer: the importance of HER-2 status

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900373-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900373-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900373-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900373-3

7 January 2021

based on heuristic

inferred from DOI database lookup

BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900373-3

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900373-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I trial of afatinib plus vinorelbine in Japanese patients with advanced solid tumors, including breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900373-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900373-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900373-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900373-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Trastuzumab beyond progression: overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900373-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900373-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900373-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900373-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Therapeutic approaches for HER2-positive brain metastases: circumventing the blood-brain barrier.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900373-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER2-positive breast cancer brain metastases.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900373-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900373-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900373-3

7 January 2021

based on heuristic

inferred from DOI database lookup

The role of efflux and uptake transporters in [N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine (GW572016, lapatinib) disposition and drug interactions.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900373-3

7 January 2021

based on heuristic

inferred from DOI database lookup

CNS metastases in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900373-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Brain metastases in HER2-positive breast cancer: the evolving role of lapatinib

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900373-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Human epidermal growth factor receptor 2-positive breast cancer and central nervous system metastases

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900373-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy of the irreversible ErbB family blocker afatinib in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)-pretreated non-small-cell lung cancer patients with brain metastases or leptomeningeal disease

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900373-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(15)00373-3

2 references

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26596672%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

PubMed publication ID

2 references

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26596672%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q27853272&oldid=2119127360"